<- Go home

Added to YB: 2024-03-25

Pitch date: 2023-12-31

NTRA [bullish]

Natera, Inc.

+276.05%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$61.68

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Alger Mid Cap Growth Fund Portfolio Holding: Natera, Inc.

NTRA: Specialty lab for genetic testing in reproductive health, oncology & transplants. Q3 beat on revenue, Signatera volume & margins drove guidance raise. Proprietary cell-free DNA platform powers prenatal (NIPT), cancer recurrence (Signatera) & organ rejection (Prospera) tests.

Read full article (1 min)